Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14452MR)

This product GTTS-WQ14452MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14452MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12125MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ8495MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ13352MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ3618MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ4744MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ9972MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ6559MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ13540MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW